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Abstract: Background: Thyroid cancer is the most common endocrine malignancy, with papillary
thyroid carcinoma (PTC) being the most common (85–90%) among all the different types of
thyroid carcinomas. Cancer cells show metabolic alterations and, due to their rapid proliferation,
an accumulation of reactive oxygen species, playing a fundamental role in cancer development and
progression. Currently, the crosstalk among thyrocytes metabolism, redox balance and oncogenic
mutations remain poorly characterized. The aim of this study was to investigate the interplay among
metabolic alterations, redox homeostasis and oncogenic mutations in PTC-derived cells. Methods:
Metabolic and redox profile, glutamate-cysteine ligase, glutaminase-1 and metabolic transporters
were evaluated in PTC-derived cell lines with distinguished genetic background (TPC-1, K1 and
B-CPAP), as well as in an immortalized thyroid cell line (Nthy-ori3-1) selected as control. Results:
PTC-derived cells, particularly B-CPAP cells, harboring BRAF, TP53 and human telomerase reverse
transcriptase (hTERT) mutation, displayed an increase of metabolites and transporters involved
in energetic pathways. Furthermore, all PTC-derived cells showed altered redox homeostasis,
as reported by the decreased antioxidant ratios, as well as the increased levels of intracellular oxidant
species. Conclusion: Our findings confirmed the pivotal role of the metabolism and redox state
regulation in the PTC biology. Particularly, the most perturbed metabolic phenotypes were found in
B-CPAP cells, which are characterized by the most aggressive genetic background.
Keywords: papillary thyroid carcinoma; metabolomics; metabolic profile; oxidative stress; cancer
cell metabolism
1. Introduction
Metabolic reprogramming in tumor has been reported as one of the “hallmarks of cancer”,
providing proliferating cancer cells with the bioenergetic and biosynthetic metabolites and biosynthetic
advantages needed for neoplastic transformation [1]. This adaptation results in dysregulation of
several pathways, including glycolysis, glutaminolysis, citric acid cycle, pentose phosphate shunt, and
lipid metabolism [2]. A close relationship between these alterations in cancer metabolism and both
oncogenes and tumor suppressors signaling is indicated by a number of evidences [3]. Additionally,
malignant transformation in cancer cells has been largely associated with increased reactive oxygen
species (ROS) levels [4,5], which in the tumor microenvironment are responsible for the activation
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of signaling pathways (PIP3K, MAPK/ERK, HIF, and NF-Kb signaling pathways) necessary for
tumorigenesis and cell survival [6]. Oncogenic mutations and metabolic alterations allow cancer
cells to counteract the oxidative stress resulting from the accumulation of ROS by upregulating
the antioxidant system mainly due the activity of transcriptional targets such as the nuclear factor
(erythroid-derived 2)-like 2 (NRF2) [6] and overexpressing enzymes involved in the biosynthesis of
antioxidant species, such as reduced glutathione (GSH) and cysteine [7].
The resulting delicate balance between intracellular ROS and antioxidant needs is closely
dependent on various metabolic pathways, generating a crosstalk between metabolism and redox
homeostasis [8].
Amongst the family of endocrine cancers, thyroid carcinomas is the most frequent manifestation.
The majority of thyroid tumors are differentiated forms, with 85–90% of them represented by papillary
thyroid carcinoma (PTC) [9]. Recurrent somatic genetic alterations in known oncogenes have been
identified in PTC, with BRAF, RAS, and RET/PTC rearrangements occurring in 29–83%, 10–20%,
and ~20% of PTC, respectively [9–11]. Moreover, hTERT) promoter mutations, conferring increased
promoter activity of the TERT gene, have been observed in approximately 11% of PTC with aggressive
behavior [12], and together with other genetic alterations, such as TP53 mutations, are found to be
associated with aggressive forms of PTC [13].
BRAFV600E mutation and RET rearrangements lead to constitutive activation of MAPK signaling
pathway, which mostly regulates cell growth, differentiation, and survival [10]. Although genomics,
transcriptomics and proteomics studies have contributed to a better understanding of PTC, they
do not completely characterize the cancer phenotype closer to the cancer metabolome and redox
balance [14]. To the best of our knowledge, there is no evidence yet about a possible connection
between altered metabolism, redox homeostasis and the different genetic backgrounds in PTC. In this
work, we investigate the metabolic changes and the redox status of three PTC-derived cell lines (TPC-1,
K1, and B-CPAP), carrying a different genetic background. An immortalized normal thyrocytes cell line
Nthy-ori3-1, that is negative for the aforementioned PTC genetic mutations, was used for comparison
(Table 1).
Table 1. Mutational status of cell lines.
Cell Lines Tissue Origin hTERT BRAFV600E RET/PTC TP53
B-CPAP PTC C228T GTG -> GAG * Wt GAC -> TAC
K1 PTC C228T GTG -> GAG ** Wt wt
TPC-1 PTC C228T wt RET/PTC1 wt
Nthy-ori 3-1 NTT wt wt wt wt
* homozygous; ** heterozygous; NTT: normal thyroid tissue; PTC: papillary thyroid carcinoma; wt: wild type [15].
2. Results
2.1. Metabolomic Profiles of PTC-Derived Cell Lines
Metabolites, involved in glycolysis, tricarboxylic acid (TCA) cycle, and glutaminolysis, play
a crucial role in the metabolic adaptation of cancer cells. Data obtained from the metabolomic targeted
analysis were compared to the “control” cells, to evaluate significantly changes in metabolites. p values,
obtained from Student t-test, were corrected by using Holm–Bonferroni sequential correction method
(Table S1). The data obtained from of PTC-derived cells were compared to the Nthy-ori3-1cells,
used as control, to evaluate significant changes in metabolites. The results revealed an increase
of metabolites associated with glycolysis [Glucose-6-phosphate/fructose-6-phosphate (G6P/F6P),
dihydroxyacetone phosphate (DHAP), glyceraldheide-3-phosphate (GAP), 2/3-phosphoglycerate
(2/3PG), and phosphoenolpyruvate (PEP)] and a decrease of fructose-1,6-phosphate (F1, 6P) and lactate
in B-CPAP compared to both control and other PTC-derived cells (Figure 1). Glucose and pyruvate
were significantly decreased only in TPC-1 and K1 compared to control cells. Similarly, fumaric acid
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was increased only in the B-CPAP cell line, while the other members of the TCA cycle, namely citric
acid and α-ketoglutarate, were significantly increased in B-CPAP, K1, and TPC-1 cells compared to
controls. Conversely, acetyl CoA, isocitric acid, succinyl-CoA, succinic acid, and oxaloacetate levels
were significantly decreased in all cancer cells (Figure 2A). Regarding the glutaminolysis pathway,
glutamine was increased in all cancer cells, while glutamate was significantly increased only in B-CPAP
and significant decreased in K1 compared to control cells (Figure 2B).
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Figure 1. Glycolytic Pathway in PTC-derived cells. Metabolic alterations in glycolysis measured
using ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS).
Bar graphs indicate the relative concentration (peak areas) of the metabolites expresses as ranks.
All experiments were performed three times independently, each time in triplicate to confirm the
results. Statistical analyses were performed by Student t-test. Results were considered significant when
* p < 0.05, ** p < 0.01, *** p < 0.001.
2.2. Expression of GLUT1 and MCT4 Transporters and Glucose Uptake Results
To better characterize changes in the energetic mechanisms of PTC-derived cells, immunofluorescence
analysis of the two transporters for glucose (GLUT1) and lactic acid (MCT4) was performed along with
glucose uptake measurement using the fluorescent glucose analog 2-NBDG. These analyses showed
Nthy-ori3-1 and TPC-1 cells were barely positive for both carriers expression (Figure 3A,B) while K1 and,
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mostly, B-CPAP cells were positive for GLUT1 and MCT4 (Figure 3E–H). Similarly, only B-CPAP cells
showed a significantly increased glucose uptake (Figure 3I).Metabolites 2018, 8, x FOR PEER REVIEW  4 of 16 
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Figure 2. Tricarboxylic acid cycle (TCA) and glutaminolysis pathways in PTC-derived cells.
Metabolic alterations in TCA cycle (A) and glutaminolysis (B) measured using UHPLC-MS/MS.
Bar graphs indicate the relative concentration of the metabolites. All experiments were performed three
times independently, each time in triplicate to confirm the results. Statistical analyses were performed
by Student t-test. Results were considered significant when * p < 0.05, ** p < 0.01, *** p < 0.001.
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To better characterize changes in the energetic mechanisms of PTC-derived cells, 
immunofluorescence analysis of the two transporters for glucose (GLUT1) and lactic acid (MCT4) 
was performed along with glucose uptake measurement using the fluorescent glucose analog 2-
NBDG. These analyses showed Nthy-ori3-1 and TPC-1 cells were barely positive for both carriers 
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Figur 3. Expression of GLUT-1, MCT-4 and glucose uptake in PTC-derived cells. Immun fluorescence
pattern for GLUT1 and MCT4 in Nthy-ori3-1 (A,B), TPC-1 (C,D), K1 (E,F) and B-CPAP (G,H). Nuclei
were stained with DAPI (blue). Quantification of the relative glucose uptake was performed through the
fluorescent glucose analog 2-NBDG in all cell lines (I). Data are expressed as media± SD. All experiments
were performed three times independently, each time in triplicate to confirm the results. Statistical
analyses were performed by Student t-test. Results were considered significant when * p < 0.05, ** p < 0.01,
*** p < 0.001.
2.3. Redox Alterations in PTC Cells
Redox balance is a crucial feature in the tumor development and maintenance. In order to evaluate
any possible difference in its regulation and maintenance in our cell lines, we measured antioxidants
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species, ROS levels, and electron carriers. More specifically, intracellular aminothyols, expressed
as ratio of reduced/oxidized glutathione and cysteine/cystine, were detected in PTC-derived cells
through high pressure liquid chromatography (HPLC) coupled with an electrochemical detector (ECD).
Levels of GSH/GSSG ratio were found to be significantly decreased in B-CPAP, K1 and TPC-1 cancer
cells compared to control cells (Figure 4A). The same trend was observed for the cysteine/cystine
ratio, which was significantly decreased in all cancer cells lines when compared to control (Figure 4B).
Intracellular Oxidant species were measured by using 2’,7’-dichlorofluorescein diacetate (H2-DCF-DA)
probe, which is the most widely used method to give a general measurement of oxidant production in
the cells, although it does not provide a specific information about the type of oxidant. Oxidant levels
were significantly increased in cancer cells compared to control cells (Figure 4C). Furthermore, NAD+
and NADP+ intracellular levels, measured by ultra-high performance liquid chromatography–tandem
mass spectrometry (UHPLC-MS/MS), were significant increased in B-CPAP and K1 cancer cell lines
compared to control (Figure 4D,E).Metabolites 2018, 8, x FOR PEER REVIEW  3 of 16 
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found significantly overexpressed in B-CPAP and K1 compared to the control cell line (Figure 5A).  
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Figure 4. Redox control in human thyroid cell lines. (A) GSH/GSSG ratio in human thyroid cell lines.
(B) Levels Cysteine/Cystine ratio in human thyroid cell lines. (C) Oxidant level in human thyroid
cancer cell lines, expressed as % of control (human thyroid cell line, Nthy-ori3-1) (D) Intracellular
NAD+ levels. (E) Intracellular NADP+ levels detected by UHPLC-MS/MS targeted analysis. Data are
presented as means ± SD). All experiments were performed three times independently, each time in
triplicate to confirm the results. Statistical analysis were performed by Student t-Test. Results were
considered significant when * p < 0.05, ** p < 0.01, *** p < 0.001.
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2.4. Expression of Glutamate Cysteine Ligase and Glutaminase 1
The regulation of redox balance was further investigated by evaluating the expression of
glutamate-cysteine ligase (GCL), an enzyme involved in glutathione biosynthesis. GCL levels were
found significantly overexpressed in B-CPAP and K1 compared to the control cell line (Figure 5A).Metabolites 2018, 8, x FOR PEER REVIEW  4 of 16 
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gluta ate-cysteine ligase (GCL) and GLS1 with the reference gene β-actin. (B) Expression of
gluta ate-cysteine ligase in PTC-derived and control cells. (C) Expression of glutaminase-1 in
PTC-derived and control cells. Data are expressed as fold change of expression in the control cells, and
were normalized to actin as reference gene. All experiments were performed three times independently,
each time in triplicate to confirm the results. Statistical analysis were performed by Student’s t-Test.
Results were considered significant when * p < 0.05, ** p < 0.01, *** p < 0.001.
In order to better understand the role of the glutaminolysis pathway in PTC-derived cells, the
expression of the enzyme glutaminase-1 (GLS1), which is involved in glutaminolysis, was investigated.
Our data demonstrated a significant overexpression of GLS1 in all cancer cell lines compared to
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control (Figure 5B). Moreover, despite the different genetic background, no significant differences were
observed in the GLS1 expression among all PTC-derived cells.
A summary of all the described metabolic and redox alterations is presented in Figure 6.Metabolites 2018, 8, x FOR PEER REVIEW  5 of 16 
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metabolic alterations and changes in the redox homeostasis described in the studied PTC-derived
cells. PTC-derived cells, particularly those cells harboring BRAFV600E and TP53, showed metabolic
perturbatio in the uptake of nutrient , such as glucose, as further confirmed by the expression of
transporters (GLUT1 and MCT4), and alteratio in the glycolytic and TCA ycle. TCA ycle alterations
are linked to other metabolic and biosynthesis pathway , such as the de n vo lipid biosynthesis (from
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3. Discussion
Metabolic changes and redox perturbation are common features in cancer cells. Both are
considered hallmarks of cancer and they are involved in the initiation and progression of the tumor
phenotype [1]. Several mutated oncogenes and tumor suppressor genes have been associated to
different signaling pathways affecting the tumor cell metabolism and redox status [8]. The aim of this
study was to explore and connect the metabolic rewiring and the altered redox balance together with
the different PTC-genetic profiles, to better clarify the interplay between oncogenic events, metabolic
adaptations and redox perturbation.
3.1. Metabolic Alterations in PTC Cells
Our results revealed that metabolites involved in energy production pathways, such as glycolysis,
TCA cycle and glutaminolysis, were altered in our PTC-derived cell lines. Particularly, B-CPAP cells,
harboring a genetic profile reflecting the aggressiveness of primary tumor from which derived (BRAF,
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TP53, and hTERT mutations), displayed the most perturbed metabolic phenotype, as demonstrated by
altered levels of energetic metabolites (e.g. increase of F6P, DHAP, GAP, 3PG, PEP, and decrease of
lactic acid). This higher glycolytic rate in B-CPAP cells suggests a role of the genetic background of
these cells in the regulation of metabolic pathways. Indeed, their mutations (BRAFV600E and TP53)
were found to be associated with an increased glycolysis, affecting the expression of glycolytic enzymes
and glucose transporters [16–18], both features required to accomplish the metabolic and energetic
demands of proliferating cancer cells [19]. This finding supports the interplay between oncogenic
events and metabolic modulation, from which cancer cells take advantages for the growth and survival.
These altered metabolic needs reflected also in the perturbations observed for intermediates of the
TCA cycle, supporting the hypothesis that cancer cells uncouple glycolysis from the TCA cycle to
provide different fuel sources [20,21]. A specific example is citrate, which is an intermediate of several
biochemical pathways such as de novo lipogenesis ad sterol biosynthesis [22], and is found to be
increased in both K1 and B-CPAP cells. The accumulation of citrate as a promoter of lipid synthesis
is confirmed by the concomitant increase of α-KG and glutamine. Indeed, the depletion of citrate
from the TCA cycle to sustain lipid biosynthesis is counterbalanced by glutamine with increasing
levels of α-KG [23]. The accumulation of fumarate found in B-CPAP cells could be associated with the
epithelial-to-mesenchymal transition [24], a phenomenon playing an important role in cancer initiation,
growth, invasion, dissemination, and metastasis as well as resistance to therapy [15,25].
An alternative evaluation of the cellular energetic consumption was performed by measuring the
glucose uptake and transport. Due to the higher energetic demand, cancer cells usually display an
increased glucose uptake facilitated by overexpression of glucose transporters, particularly GLUT1, in
the plasma membrane [26]. The accumulation of lactic acid resulting from the increased aerobic
glycolytic rate is counterbalanced by an increased expression of monocarboxylate transporters
(MCTs), in particular MCT4 [27–29]. In order to further confirm the high glycolytic rate, found
in PTC-derived cells, and in order to give an insight of nutrient fluxes across membranes, we analyzed,
by immunofluorescence, the expression of GLUT1 and MCT4 transporters. Accordingly, B-CPAP cells
presented a marked increase in the expression of both GLUT1 and MCT4 in their plasma membrane,
as well as the highest glucose uptake rate compared to all other cell lines analyzed, which is in line
with their hyper-glycolytic and aggressive phenotype. Moreover, B-CPAP cells showed an increase of
glutamine and glutamate, metabolites involved in glutaminolysis. Altogether, these findings support
the fundamental role of glutaminolysis in cancer cells and its connection with glycolysis. Indeed,
glutaminolysis can be exploited to replenish TCA cycle intermediates, which, as mentioned above,
are often reduced by the uncoupling of TCA cycle and glycolysis in tumors [30]. This was further
confirmed by the overexpression of GLS1, an enzyme converting glutamine into glutamate, hence
providing fuel for the TCA cycle [31], in all PTC-cells compared to control. Interestingly, wild-type
p53 plays an important role in glutamine metabolism by activating the glutaminase-2 isoform (GLS2),
which promotes energy and antioxidant production [32]. GLS2 resulted to be mainly involved in the
redox regulation, promoting glutamate production, which is then directed to the GSH biosynthesis [32].
The expression of GLS1, rather than GLS2, in our case seems to be closely related to the activity
of mutant p53 [33], and considering our goal being on the highlighting the connection of mutated
TP53 and glutamolysis, we only focused on the GLS1 expression. The increased expression of GLS1
in PTC-derived cells, particularly in B-CPAP cells, further reflect the interplay among cancer cell
metabolism and oncogenic mutations. Particularly, PTC genetic profiles with BRAFV600E and TP53
mutations showed the most perturbed metabolic phenotype, confirming the role of these oncogenic
events in the reprogramming of cancer metabolism [8].
3.2. Redox Alterations in PTC Cells
In cancer cells, redox regulation covers a fundamental role and results from oncogenic mutations
that promote altered metabolism, resulting in increased rates of ROS production [8]. Increasing
evidence reported that alteration in the metabolism resulted in a tight control of ROS and antioxidant
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production [8]. Given the known cross talk and connections between metabolic pathways and
redox balance in tumors [8], we decided to explore the redox homeostasis of PTC-derived cells.
Significant changes in the redox status were observed, such as decreased levels of both GSH/GSSG
and cysteine/cystine ratios as well as significant increase of ROS levels in all PTC-derived cells,
in agreement with their perturbed redox condition [34]. Moreover, levels of GSH were found to be lower
in PTC-derived cells compared the control cells (data not shown), supporting the presence of oxidative
stress. A further symptom of the altered redox balance in PTC is the augmented level in K1 and B-CPAP
cells of both NAD+ and NADP+, key molecules involved in the redox balance and in the antioxidant
biosynthesis, respectively [35]. Indeed, NADP+ (and its reduced form NADPH) provides reducing
power in metabolic reactions and participates to regenerate antioxidant defenses [8]. Furthermore,
the same cell lines accumulating NAD+ and NADP+ presented overexpression of GCL, enzyme
responsible for the glutathione biosynthesis and usually overexpressed in cancer [36], confirming the
redox perturbation of these tumor cells. The regulation of redox homeostasis is deeply connected to
metabolic pathways [8]. Particularly, metabolic reactions such as the conversion of glucose into G6P,
isocitric acid into αKG, malic acid into pyruvic acid and glutamine into glutamate, are involved in the
regeneration of NADPH to sustain antioxidant defenses [8]. In our data, levels of αKG, glutamine and
glutamate were found to be increased in PTC-derived cells, particularly in B-CPAP cells, supporting
the involvement of these metabolites in the redox modulation and the interplay between metabolism
and redox homeostasis.
4. Conclusions
Our study combines different analytical techniques to gain new insights into the metabolic
complexity of papillary thyroid carcinoma and allowed us to confirm the pivotal role of the interplay
between the genetic background of tumors and cancer phenotypic features, such as metabolism and
redox homeostasis. In conclusion, although the importance of metabolism in cancer cells has been
previously pointed out by a number of studies as a promising tool to understand tumor biology,
deciphering the metabolic alterations and dependencies of cancer cells still remains a great challenge
in this field. On the base of our finding, a multidisciplinary approach in cancer research could be
fundamental to define cancer susceptibility and possible dependencies to be targeted. Considering
the limit of our study, using a PTC in vitro model with only three PTC-derived cell lines, further
experiments are needed, in both cell lines and human tissues, to confirm and to deeply investigate
metabolic behavior of PTC.
5. Material and Methods
5.1. Cell Culture
The human PTC-derived TPC-1 and B-CPAP cell lines were kindly provided by Dr. Fusco
(Medical School, University Federico II of Naples, Naples, Italy), while both PTC-derived K1 cell line
and Nthy-ori3–1, Simian Virus 40 (SV40)-immortalized normal human thyrocytes were purchased
from the Health Protection Agency Culture Collections [37]. All cell lines were grown as monolayers
in culture in Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 (DMEM/F12) supplemented with
10% fetal bovine serum (FBS, Life Technologies, Milan, Italy), 100 UI/mL penicillin and 100 µg/mL
streptomycin (Merck, Milan, Italy), at 37 ◦C in a humidified 5% CO2 atmosphere.
5.2. Aqueous Metabolites Extraction
Cells were seeded in Petri dishes (100 mm) at the density of 1.8 × 106 cells and let them grow for
48 h. Then cells were harvested by scraping after removal from the dished of the growth medium.
Cells were extracted as described previously [38]. Briefly, a mixture of cold methanol and water (80:20
v/v) was added to the dishes, cells were detached and collected in EppendorfTM tubes. In order to
ensure complete cellular lysis, the extraction was combined with 10 min of ultrasonic treatment at 4
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◦C. Cell suspensions were centrifuged at 4500 rpm for 30 min at 4 ◦C. The upper aqueous phase was
separated, aliquoted in EppendorfTM tubes and dried in an EppendorfTM Concentrator Plus overnight.
5.3. Ultra High Performance Liquid Chromatography-Tandem Mass Spectrometry
Metabolites, in the aqueous dried fraction of the samples, were measured using an ultra-high
performance liquid chromatography coupled with a TSQ QuantivaTM Triple Quadrupole Mass
Spectrometer (UHPLC-MS/MS) using a targeted approach, in both positive and negative ion mode,
with an ESI source. Aqueous metabolites were acquired through selected reaction monitoring (SRM)
mass spectrometry analysis, following infusion of standard compounds, using two targeted analysis
based on the different polarity of detected compounds. For the first targeted analysis, samples
were reconstituted in 200 µL acetonitrile:water (7:3 v/v) with ammonium carbonate 0.1 M, and then
subjected to LC separation on a BEH amide HILIC column (100× 2.1 mm, 1.7 µm; Waters Ltd) with
a flow rate of 600 µL/min and mobile phase consisting of 0.1% of ammonium carbonate water
solution and acetonitrile solution. For the second targeted analysis, samples were reconstituted
in 0.1% of formic acid in water, and injected using a reversed-phase ACE Excel C18-pfp column
(150 × 2.1 mm, 2 µm; ACE). UHPLC was operated at a flow rate of 500 µL/min, with the mobile
phase consisting of a solution of 0.1% of formic acid in water (A) and a solution of 0.1% of formic
acid in acetonitrile (B) and programmed as follows: starting with 20% of A for 1.50 min, linear
increasing from 20% to 60% of A in 2.5 min, for one minute kept at this percentage, and brought
back to initial condition after 0.1 min. Both mass spectrometry analyses were performed using
a standard-mix containing 10 uM of each of the following isotope-labelled compound: [13C, 15N]
L-proline, L-leucine-d10, L-Valine-d8, L-phenylalanine d5, Succinic acid-13C and Serotonine-d4 (Merck,
Gillingham, Dorset, UK) and [13C, 15N] L-glutamate (Cambridge Isotope Laboratories, Andover, MA,
USA). The Xcalibur software (Thermos Fisher Scientific, Waltham, MA, USA) was used for data
acquisition. Putative recognition of all detected metabolites was performed by inspection of the spectra
deriving from a targeted MS/MS analysis. Metabolites with different isoforms (2/3-phosphoglicerate
and glucose-6-phosphate/fructose-6-phosphate) could not be chromatographically resolved, thus
peaks of these metabolites were considered as the sum of both isoforms. Retention times, calculated
masses, mass fragments and acquisition ion mode of the compounds are reported in Table 2. Peak areas
for each detected metabolite were normalized by total area and reported as ranks in the bar graph.
Immunofluorescence. Cells were enzymatically dissociated, cultured on previously sterilized
slides, and placed in square tissue culture dishes (quadriPERM®, Sarstedt AG & Co, Nümbrecht,
Germany). Cell cultures were maintained for 16 h at 37 ◦C in a humidified 5% CO2 atmosphere,
followed by fixation with 4% paraformaldehyde for 10 min at room temperature. Immunostaining
was performed as previously described [15] using rabbit polyclonal anti-GLUT1 (1:200; Abcam, CA,
USA) and rabbit polyclonal anti MCT4 (1:100; Abcam, Cambridge, UK) antibodies. Alexa-conjugated
(Alexa Fluor 488 or 594, Life Technologies) goat anti-rabbit IgG was 0used as secondary antibodies.
Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI).
Glucose uptake assay. Cells were seeded in 96-well plates (1 × 105 cells/mL) and incubated
for 24 h. After incubation, plates were washed with PBS, followed by the addition of 50 µM of
2-[N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino]-2-deoxy-Dglucose (2-NBDG, fluorescently-tagged
glucose derivative, N13195; Invitrogen), which was incubated for 30 min. External 2-NBDG was
washed off and replaced with PBS. Relative glucose uptake was measured by reading the fluorescence
emitted using a micro plate reader (Infinite 200, Tecan, Salzburg, Austria) at a controlled temperature
of 37 ◦C. The measurement was performed using an excitation of 485 nm and an emission of 530 nm.
Protein Quantification. Cells were seeded in 6-well plates (1 × 105 cells/mL) and incubated for
48 h and 72 h for western blot and intracellular aminothyiols determination, respectively. Then cells
were washed twice with ice-cold PBS and lysed with CelLytic M (Merck, Milan, Italy) supplemented
with protease and phosphatase inhibitor mini tables (Thermos Fisher Scientific, Waltham, MA, USA).
Cell were then incubated for 15 min on ice before centrifugation at 12,500 g at 4 ◦C for 7 min and
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stored at –20 ◦C prior quantification. Protein quantification was performed by using Bradford Assay.
Calibration curve was generated using bovine serum albumin (BSA) in lysis buffer, at different
concentrations (0.1 mg/mL–10 mg/mL). 500 µL of Bradford reagent solution was incubated with
either 10 µL of standard or protein sample at room temperature for 5 min. The absorbance was
measured at 595 nm using a micro plate reader (Infinite 200, Tecan, Salzburg, Austria) at a controlled
temperature of 37 ◦C. The equation of the line of the standard curve was used to calculate the protein
concentration of the cell samples.
Table 2. Mass spectral data of detected compounds using UHPLC/MS-MS.
Compound RT Precursorion(m/z)
Production
(m/z) Polarity Column
2/3 Phosphoglycerate 4.02 185.000 97.065 Negative BEH amide
Acetyl-CoA 3.65 810.225 303.049 Positive BEH amide
α-ketoglutarate 3.35 145 101.123 Negative BEH amide
Citric acid 1.32 191 111 Negative C18-pfp
Dihydroxyacetone phosphate 3.88 169 97.143 Negative BEH amide
Glucose-6-phosphate/Fructose 6 phosphate 4.05 259 97.077 Negative BEH amide
Fructose bisphosphate 4.24 339 97.084 Negative BEH amide
Fumaric Acid 3.48 115 71.172 Negative BEH amide
Glucose 2 179 89 Positive BEH amide
Glutamic Acid 0.74 148 84.15 Positive C18-pfp
Glutamine 0.72 153.1 89.169 Positive C18-pfp
Glyceraldhehide-3-phosphate 3.83 169.009 97 Negative BEH amide
Isocitric acid 1.71 191 111 Negative C18-pfp
Lactic Acid 2.5 89 43 Negative BEH amide
Malic Acid 3.67 133 115.081 Negative BEH amide
NAD+ 3.82 664.1 136.237 Positive BEH amide
NADP+ 4.15 744.1 136.2 Positive BEH amide
Oxaloacetate 3.34 131 87.084 Negative BEH amide
Phosphoenolpyruvate 3.94 167 79.081 Negative BEH amide
Pyruvic acid 2.75 87 43 Negative BEH amide
Succinic acid 3.51 117 73 Negative BEH amide
Succynil-CoA 3.92 868.1 361.214 Positive BEH amide
Compound name, retention time, calculated masses, mass fragments, polarity and column for all detected metabolites.
Determination of intracellular aminothyols level. GSH, GSSG, Cysteine and Cystine levels
were determined in B-CPAP, K1, TPC-1 and Nthy-ori 3-1 cell lines with EC-HPLC quantification,
using the method described by Khan et al [39]. Cells were seeded in 6-well plates (1 × 105 cells/mL)
and incubated for 72 h. After incubation, cells were scraped and extracted with 150 µL of 10%
meta-phosphoric acid and 150 µL of 0.05% trifluoroacetic acid (TFA) (Merck, Milan, Italy) solution.
The solution was centrifuged and the resulting clear supernatant was injected into the Agilent 1260
infinity HPLC system (Agilent Technologies, Santa Clara, USA) equipped with an electrochemical
detector (DECADE II Antec, Leyden, The Netherlands) and an Agilent interface 35900E. A calibration
curve was created using standards of GSH, GSSG, Cysteine and Cystine (Merck, Milan, Italy) injected
at different concentrations. Data were collected and expressed as ng of GSH, GSSG, Cysteine and
Cystine to µg of protein(s) measured by Bradford assay as described above.
Determination of intracellular ROS production. Intracellular ROS were measured in B-CPAP,
K1, TPC-1 and immortalized non tumoral Nthy-ori 3-1 cell lines, seeded in 96-well plates (7.5 ×
103 cells/mL), washed with PBS solution and incubated for 30 min with 2′,7′-dichlorofluorescin
diacetate (H2-DCF-DA, Merck, Milan, Italy) 10 µM in PBS, as previously described [40]. H2-DCF-DA
was then removed and cells were exposed to PBS. ROS production was determined by measuring the
fluorescence emitted (excitation of 490 nm and an emission of 520 nm) after 2 h using a micro plate
reader (Infinite 200, Tecan, Salzburg, Austria) at a controlled temperature of 37 ◦C.
Western blot analysis. Immunoblotting experiments were performed with the following
antibodies: mouse monoclonal antibody directed against actin (clone AC-40) (Merck, Milan, Italy) and
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two rabbit polyclonal antibodies directed against Glutaminase (ab93434; Abcam, Cambridge, UK) and
GCL (Merck, Milan, Italy), respectively.
For expression analysis, equal amounts (20 µg/lane) of proteins were electrophoresed on SDS-10%
polyacrylamide gels (Bio-Rad, Hercules, CA, USA). Protein-sample preparation was used for all gels,
which were electrotransferred onto nitrocellulose membrane (Osmonics, Westborough, MA, USA).
Membranes were stained with 0.5% (wt/vol.) Ponceau S red (ICN Biomedicals, Aurora, Ohio, USA),
blocked in TBS containing 0.05% Tween 20 (Merck, Saint Louis, MO, USA) and 5% BSA (Sigma
Aldrich), and incubated with the specific primary antibodies diluted in blocking buffer. Membranes
were incubated with anti-mouse or anti-rabbit horseradish peroxidase conjugated IgGs (Santa
Cruz Biotechnology, CA, USA). Immunoreactive bands were identified with a chemiluminescence
detection system, as described by the manufacturer (Supersignal Substrate, Pierce, Rockford, IL, USA).
Densitometric analysis of immunoreactive bands was performed using the program ImageJ (JAVA,
Wayne Rasband, National Institute of Health, USA).
Statistical Analysis. Experimental results were subjected to Student t-Test with the GraphPad
prism v5.0 software (GraphPad software, La Jolla, USA). Statistical significance was calculated
comparing average of results from each PTC-derived cells with control cells. Data are presented
as means ± standard deviation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/9/2/23/s1,
Figure S1: Nucleotides levels in PTC-derived cells. Figure S2: Amino acids levels in PTC-derived cells. Table S1:
Holm-Bonferroni sequential correction of p values obtained from unpaired Student t-test.
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